Skip to main content
. 2010 Dec 1;5(12):e15105. doi: 10.1371/journal.pone.0015105

Figure 12. Effects of 17-O-acetylacuminolide (AA) on IKKβ activity.

Figure 12

Human, recombinant IKKβ (5 ng) was incubated in the presence of increasing concentrations of AA as outlined in the manufacturer's detailed protocol. AA dose-dependently inhibited IKKβ activity with an EC50 of 5.2 µgmL−1. Results are average of three independent experiments ±SD. Data was analyzed using one-way ANOVA, with Tukey's post hoc test (* p<0.05, ** p<0.01, *** p<0.001).